Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
CD-388 by Cidara Therapeutics for Influenzavirus A Infections: Likelihood of Approval
CD-388 is under clinical development by Cidara Therapeutics and currently in Phase I for Influenzavirus A Infections. According to GlobalData,...
CD-388 by Cidara Therapeutics for Influenzavirus B Infections: Likelihood of Approval
CD-388 is under clinical development by Cidara Therapeutics and currently in Phase I for Influenzavirus B Infections. According to GlobalData,...
CD-388 by Cidara Therapeutics for Seasonal Influenza: Likelihood of Approval
CD-388 is under clinical development by Cidara Therapeutics and currently in Phase II for Seasonal Influenza. According to GlobalData, Phase...
CD-388 by Cidara Therapeutics for Pandemic Influenza: Likelihood of Approval
CD-388 is under clinical development by Cidara Therapeutics and currently in Phase II for Pandemic Influenza. According to GlobalData, Phase...